Literature DB >> 13749902

A comparison of the sensitivity to p-aminosalicylic acid of tubercle bacilli from South Indian and British patients.

J B SELKON, T V SUBBAIAH, A L BHATIA, S RADHAKRISHNA, D A MITCHISON.   

Abstract

In a comparison of home and sanatorium treatment for tuberculous patients in India, pretreatment cultures of tubercle bacilli showed a higher average level of resistance to p-aminosalicyclic acid (PAS) than pretreatment cultures from a representative sample of patients in Great Britain. The investigation described in the present paper was therefore undertaken to find out the nature of the difference in the PAS sensitivity of cultures from Indian and British patients. In this investigation, carried out jointly at the Tuberculosis Chemotherapy Centre, Madras, and the Postgraduate Medical School of London, sputum specimens from 147 Indian and 93 British patients were cultured and subjected to sensitivity tests. The tests were set up on slopes containing various concentrations of PAS and inoculated with 10(5) viable units of the cultures, and the minimal concentrations of PAS inhibiting the growth of 20, 50 and 100 colonies were determined. According to the 20-colony end-point-the one commonly used in routine sensitivity tests-the Indian strains were significantly more resistant than the British strains. This difference in sensitivity was not apparent, however, in either the 50-colony or the 100-colony results. The presence of a small proportion of resistant organisms was found to be a general characteristic of the Indian strains, but did not appear to be related to any special tendency for the patient to fail to respond to treatment with PAS. Since a chance increase in the inoculum size might well affect the 20-colony results, the authors recommend a tenfold decrease in the size of the inoculum used in routine PAS-sensitivity tests on Indian patients.

Entities:  

Keywords:  MYCOBACTERIUM TUBERCULOSIS/pharmacology; PARA-AMINOSALICYLIC ACID/pharmacology

Mesh:

Substances:

Year:  1960        PMID: 13749902      PMCID: PMC2555621     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  The properties of para-aminosalicylic acid-resistant Mycobacterium tuberculosis var. hominis.

Authors:  M TSUKAMURA
Journal:  Am Rev Tuberc       Date:  1957-04

2.  Bacteriological aspects of a survey of the incidence of drug-resistant tubercle bacilli among untreated patients.

Authors:  D A MITCHISON; J B SELKON
Journal:  Tubercle       Date:  1957-04

3.  Comparison of solid and liquid medium sensitivity tests of tubercle bacilli to para-aminosalicylic acid.

Authors:  D A MITCHISON; M MONK
Journal:  J Clin Pathol       Date:  1955-08       Impact factor: 3.411

4.  THE BACTERICIDAL PROPERTIES OF THE QUATERNARY SALTS OF HEXAMETHYLENETETRAMINE : III. THE RELATION BETWEEN CONSTITUTION AND BACTERICIDAL ACTION IN THE QUATERNARY SALTS OBTAINED FROM HALOGENACETYL COMPOUNDS.

Authors:  W A Jacobs; M Heidelberger; C G Bull
Journal:  J Exp Med       Date:  1916-05-01       Impact factor: 14.307

  4 in total
  10 in total

1.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India.

Authors:  C Mani; N Selvakumar; S Narayanan; P R Narayanan
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

2.  The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. I. Homogeneity of the investigation and a critique of the virulence test.

Authors:  D A MITCHISON; A L BHATIA; S RADHAKRISHNA; J B SELKON; T V SUBBAIAH; J G WALLACE
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

3.  Prevalence and early attack rate of tuberculosis among close family contacts of tuberculous patients in South India under domiciliary treatment with isoniazid plus PAS or isoniazid alone.

Authors:  C V RAMAKRISHNAN; R H ANDREWS; S DEVADATTA; W FOX; S RADHAKRISHNA; P R SOMASUNDARAM; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

4.  Isoniazid plus thioacetazone compared with two regimens of isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis in South Indian patients.

Authors: 
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

5.  Influence of segregation to tuberculous patients for one year on the attack rate of tuberculosis in a 2-year period in close family contacts in South India.

Authors:  C V RAMAKRISHNAN; R H ANDREWS; S DEVADATTA; W FOX; S RADHAKRISHNA; P R SOMASUNDARAM; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

6.  Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis.

Authors: 
Journal:  Br Med J       Date:  1973-04-07

7.  Identification of tubercle bacilli from Indian patients with pulmonary tuberculosis.

Authors:  K L THOMAS; S JOSEPH; T SUBBAIAH; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

8.  Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate.

Authors:  S DEVADATTA; R H ANDREWS; J H ANGEL; A L BHATIA; W FOX; B JANARDHANAM; S RADHAKRISHNA; C V RAMAKRISHNAN; T V SUBBAIAH; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

9.  A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India.

Authors: 
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

10.  ACONCURRENT COMPARISON OF INTERMITTENT (TWICE-WEEKLY) ISONIAZID PLUS STREPTOMYCIN AND DAILY ISONIAZID PLUS PAS IN THE DOMICILIARY TREATMENT OF PULMONARY TUBERCULOSIS; TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS.

Authors:  A LOTTE; F HATTON; S PERDRIZET; A ROUILLON
Journal:  Bull World Health Organ       Date:  1964       Impact factor: 9.408

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.